Deacetylase inhibitors: a novel class of drugs for immune system malignancies
Exploring combinatorial approaches in acute myeloid leukemia (AML) treatment
Francesco Lo Coco
Where will leukemia research go next?
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients